In the Trastuzumab for Gastric Cancer (ToGA) trial, trastuzumab combined with chemotherapy improved the overall survival of HER2‐positive patients with advanced gastric or gastroesophageal junction cancer by roughly 3 months (Bang et al., 2010). The gene discussed is ERBB2; the disease is gastric cancer.